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Inhibition of GABAergic
Neurotransmission by HIV-1 Tat and
Opioid Treatment in the Striatum
Involves µ-Opioid Receptors
Changqing Xu and Sylvia Fitting*
Department of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, USA
Due to combined antiretroviral therapy (cART), human immunodeficiency virus type
1 (HIV-1) is considered a chronic disease with high prevalence of mild forms of
neurocognitive impairments, also referred to as HIV-associated neurocognitive disorders
(HAND). Although opiate drug use can exacerbate HIV-1 Tat-induced neuronal damage,
it remains unknown how and to what extent opioids interact with Tat on the GABAergic
system. We conducted whole-cell recordings in mouse striatal slices and examined
the effects of HIV-1 Tat in the presence and absence of morphine (1µM) and damgo
(1µM) on GABAergic neurotransmission. Results indicated a decrease in the frequency
and amplitude of spontaneous inhibitory postsynaptic currents (sIPSCs) and miniature
IPSCs (mIPSCs) by Tat (5–50 nM) in a concentration-dependent manner. The significant
Tat-induced decrease in IPSCs was abolished when removing extracellular and/or
intracellular calcium. Treatment withmorphine or damgo alone significantly decreased the
frequency, but not amplitude of IPSCs. Interestingly, morphine but not damgo indicated
an additional downregulation of the mean frequency of mIPSCs in combination with Tat.
Pretreatment with naloxone (1µM) and CTAP (1µM) prevented the Tat-induced decrease
in sIPSCs frequency but only naloxone prevented the combined Tat and morphine effect
on mIPSCs frequency. Results indicate a Tat- or opioid-induced decrease in GABAergic
neurotransmission via µ-opioid receptors with combined Tat and morphine effects
involving additional opioid receptor-related mechanisms. Exploring the interactions
between Tat and opioids on the GABAergic system may help to guide future research on
HAND in the context of opiate drug use.
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INTRODUCTION
Even though severe cases of human immunodeficiency virus type 1 (HIV-1)-associated dementia
have been reduced due to the introduction of combined antiretroviral therapy (cART),
30–50%-infected individuals suffer fromHIV-1-associated neurocognitive disorders (HAND) (Bell
et al., 1998; Dore et al., 1999; Sacktor et al., 2002; Antinori et al., 2007; Ellis et al., 2007; Heaton et al.,
2011; Saylor et al., 2016). HAND is specifically enhanced in the context of drug use, such as opiates,
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with worsening the consequences of HIV-1 in the central nervous
system (CNS) (Bell et al., 1998; Arango et al., 2004; Anthony
et al., 2005; Lan et al., 2015). Experimental models of acquired
immune deficiency syndrome (AIDS) have further indicated an
increase in virus and disease progression by opiates (Pérez-
Casanova et al., 2007; Noel et al., 2008; Rivera-Amill et al., 2010;
Bokhari et al., 2011; Hu et al., 2012; Masvekar et al., 2015). HIV-1
specifically targets subcortical and cortical areas of the brain, with
HIV-1 positive individuals displaying deficits in sensorimotor
function, executive function, learning andmemory, and attention
(Berger and Nath, 1997; Berger and Arendt, 2000; Heaton et al.,
2011; Scott et al., 2011). The striatum is one of the regions
with the highest viral burden (Kure et al., 1990; Berger and
Arendt, 2000; Kumar et al., 2007) and rich in opioid receptor-
expressing cells. Animal in vivo and in vitro studies focusing on
the striatumhave identified exacerbated behavioral and structural
changes by opioids in the presence of the HIV-1 transactivator
of transcription (Tat) corresponding to a HAND-associated
phenotype (Fitting et al., 2010, 2012, 2014).
It has been demonstrated that Tat interacts with different
receptors, including chemokine, NMDA, and G protein coupled
receptors (Albini et al., 1998; Haughey et al., 2001; Prendergast
et al., 2002; Eugenin et al., 2003; Feligioni et al., 2003;
Longordo et al., 2006; Shin et al., 2012) leading to deficits in
neurotransmission (Sabatier et al., 1991; Behnisch et al., 2004;
Brailoiu et al., 2008; Hargus and Thayer, 2013), excitotoxic events
(Haughey et al., 1999; Feligioni et al., 2003), synaptodendritic
injury (Bertrand et al., 2014), and eventually neuronal death.
Although synergism has been demonstrated between opioids
and Tat on the glutamatergic system (Gurwell et al., 2001;
Gupta et al., 2010; Zou et al., 2011; Fitting et al., 2014;
Liu et al., 2016), not much is known about how HIV-1 Tat
interacts with opioids on the GABAergic neurotransmitter
system and whether the exacerbating effects of opioids in
the presence of Tat can also be attributed to its effects on
the GABAergic system. It is well known that opioids inhibit
GABAergic neurotransmission in the striatum (Johnson and
North, 1992; Klitenick et al., 1992; Bergevin et al., 2002)
and recently the GABAergic inhibitory system has also been
implicated in neuroAIDS, with the GABAergic inhibitory system
being downregulated in HIV-1-positive patients with HAND
(Gelman et al., 2012; Buzhdygan et al., 2016). In experimental
studies it is less clear as Tat has been reported to increase
inhibitory synapses and neurotransmission (Brailoiu et al., 2008;
Hargus and Thayer, 2013), whereas other studies have reported
unchanged or decreased inhibitory synapses or inhibitory
release (Musante et al., 2010; Zucchini et al., 2013; Xu et al.,
2016).
Thus, the present study investigated the effects of HIV-1
Tat alone and in combination with opioids by focusing on
the GABAergic system. Results indicated a Tat and opioid-
induced decrease in GABAergic neurotransmission via µ-opioid
receptors with the combined effects of Tat and morphine
involving more than just µ-opioid receptor-related mechanisms.
Exploring the interactions between Tat and opioids on multiple
neurotransmitter systems is important in understanding its
effects on neuronal function and neuronal network processing.
MATERIALS AND METHODS
Electrophysiology
Slice Preparation
All animal experiments were performed according to protocols
approved by the Animal Care and Use Committee the University
of North Carolina at Chapel Hill. Striatal slices were prepared
from 14 to 24-day-old male and female C57BL/6J mice (The
Jackson Laboratory, Bar Harbor, ME). Mice were euthanized
using isoflurane, decapitated, and brains were placed into ice-
cold sucrose buffer containing (in mM): 254 sucrose, 10 D-
glucose, 26 NaHCO3, 2 CaCl2, 2 MgSO4, 3 KCl, and 1.25
NaH2PO4, saturated with 95% O2/5% CO2, at pH 7.4, 300
mOsm. Brains were cut into 300µMcoronal sections through the
striatum using a VT 1000S microtome (Leica, Deerfield, IL) and
placed into a holding chamber at 33◦C for 30min in a mixture of
50% sucrose saline and 50% artificial cerebrospinal fluid (aCSF)
containing (in mM): 128 NaCl, 10 D-glucose, 26 NaHCO3, 2
CaCl2, 2 MgSO4, 3 KCl, and 1.25 NaH2PO4. Slices were then
maintained at room temperature in aCSF bubbled continuously
with 95% O2/5% CO2.
Recordings and Analyses
Slices were transferred to a recording chamber (Warner
Instruments, Hamden, CT) and continuously perfused with
aCSF at 2–3mL/min at ∼33◦C (Warner SC-20, Hamden,
CT). Recordings were made in striatal medium spiny neurons
(MSNs) located in the dorsolateral striatum that mainly integrate
sensorimotor information (Pennartz et al., 2009) and are
specifically affected in HIV-1 positive individuals (Bauer et al.,
2005). Striatal MSNs were visualized using an Axio Examiner
A1 microscope (Zeiss, Thornwood, NY) equipped with using
differential interference contrast (DIC) and Dodt contrast. Patch-
clamp recordings in whole-cell mode were obtained using a
MultiClamp 700B amplifier (Axon Instruments, Union City,
CA) and digitized using Digidata 1550A and pClamp 10.0
software (Molecular Devices, Sunnyvale, CA). Patch pipettes
were glass capillaries with a filament (Narishige, Greencale, NY)
pulled using a PC-10 puller (Narishige, Greencale, NY, #GD-1.2).
The pipette internal solution used for whole-cell patch-clamp
experiments consisted of (in mM) unless otherwise stated: 140
KCl, 0.1 CaCl2, 5 EGTA, 10HEPES, 4 ATP-Mg
2+, 0.4 GTP-2Na+,
1 QX314 (Lidocaine N-ethyl bromide), pH 7.2, 290 mOsm. The
tip resistance of the patch electrode filled with internal solution
was ∼5 M. Recordings were conducted immediately following
treatment application and recording was conducted over a
5min time period. Inhibitory postsynaptic currents (IPSCs) were
recorded in the presence of the ionotropic glutamate receptor
blockers 6,7-dinitroquinoxaline-2,3-dione (DNQX, 20µM) and
2-amino-5-phosphopentanoate (AP-5; 20µM), added to the
superfusing aCSF. Spontaneous (s) and miniature (m) IPSCs
were recorded at a holding potential of−70mV and collected for
5min for each treatment. The mIPSC recordings were obtained
in the presence of 1µM tetrodotoxin (TTX). Series resistance was
monitored throughout the experiment. If the series resistance was
unstable and changed >15% during the experiment, the cell was
discarded. Signals were filtered at 2 kHz and digitized at 10 kHz.
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The Minianalysis software (Version 6.0.8; Synaptosoft, Decatur,
GA) was used to perform off-line analysis.
Treatments
HIV-1 Tat1−86 (5–50 nM, rtat HIV-1 IIIB, ImmunoDX, Woburn,
MA), morphine sulfate (1 µM, NIDA Drug Supply System,
Baltimore, MD) damgo (1µM, Tocris, Ellisville, MO), naloxone
(1 µM, Sigma-Aldrich, St. Louis, MO), and CTAP (D-Phe-
Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; 1µM, Tocris, Ellisville,
MO) were dissolved in distilled water and administered by
bath application. For the control we used bath application
of distilled water by itself. As an additional control for Tat,
we used heat-inactivated Tat1−86. Tat1−86 (50 nM) was heat-
inactivated by incubation at 85◦C for 30min. Even though the
concentration of Tat in the cerebral spinal fluid (CSF) has been
reported at 1.14 nM (16 ng/mL) (Westendorp et al., 1995), the Tat
concentration utilized in this study is generally accepted (Mayne
et al., 2000; Haughey et al., 2001; Prendergast et al., 2002; Speth
et al., 2002; Singh et al., 2004; Wallace et al., 2006; Brailoiu
et al., 2008; Fitting et al., 2014). Opioid concentrations were
based on previous studies (Johnson and North, 1992; Bergevin
et al., 2002; McQuiston, 2007). DNQX (6,7-dinitroquinoxaline-
2,3-dione, 20µM), AP-5 (DL-2-amino-5-phosphonovaleric acid,
20µM), and TTX (tetrodotoxin, 1µM) were purchased from
Tocris (Ellisville, MO). To manipulate levels we used three
different experimental conditions: (1) aCSF without calcium, (2)
aCSF with cadmium chloride (CdCl2, 200µM, Sigma-Aldrich,
St. Louis, MO), which blocks high and low threshold voltage-
dependent calcium channels, and (3) endoplasmic reticulum
calcium pump inhibitor thapsigargin (1µM, Sigma-Aldrich, St.
Louis, MO) that depletes the intracellular calcium stores.
Statistics
All numerical values are expressed as mean ± standard error
of the mean (SEM). Data were analyzed using paired Student’s
t-tests. An alpha level of p< 0.05 was considered significant.
RESULTS
Tat Concentration Dependent Effects on
IPSCs in Striatal Slices
To explore the effects of Tat on GABergic neurotransmission
patch-clamp recordings were performed on striatal MSNs
(Figure 1). sIPSCs and mIPSCs were confirmed by the
application of GABAA receptor antagonist bicuculline (data
not shown). The representative traces of sIPSCs before and
after Tat application (5–50 nM) are shown in Figure 1A. As
shown in Figure 1B, the mean (±SEM) frequency of sIPSCs
(Hz) were as follows - for control: 1.34 ± 0.39, for Tat (5 nM):
1.03 ± 0.28, for Tat (10 nM): 0.91 ± 0.22, for Tat (50 nM):
0.81 ± 0.18; n = 13. A significant Tat effect was noted on
sIPSCs, with all Tat concentrations demonstrating decreased
mean frequency of sIPSCs compared to control [control vs. Tat
(5 nM): t(12) = 2.6, p = 0.023, control vs. Tat (10 nM): t(12) =
2.5, p = 0.027, control vs. Tat (50 nM): t(12) = 2.6, p = 0.023]
and Tat (10 nM) significantly differing from Tat [50 nM; t(12)
= 2.3 p = 0.039]. As depicted in Figure 1C, the mean (±SEM)
amplitude of sIPSCs (pA) were as follows - for control: 37.40 ±
4.09, for Tat (5 nM): 41.30 ± 3.94, for Tat (10 nM): 43.82 ± 4.00,
for Tat (50 nM): 45.98 ± 3.74; n = 13. In contrast to mean
sIPSC frequency, the mean amplitude of sIPSCs indicated only
a significant increase by Tat (50 nM) compared to control [t(12)
= 2.7, p = 0.018] and compared to Tat (5 nM) [t(12) = 2.5, p
= 0.027]. To assess mIPSCs, TTX was added to the bath to
eliminate large-amplitude, action potential-dependent IPSCs. As
shown in Figure 1D, the mean (±SEM) frequency of mIPSCs
(Hz) were as follows - for control: 1.10 ± 0.36, for Tat (5 nM):
1.06 ± 0.35, for Tat (10 nM): 0.92 ± 0.32, for Tat (50 nM):
0.79 ± 0.30; n = 15. A concentration dependent decrease in
the frequency of mIPSCs by Tat was noted in the presence of
TTX, with all conditions indicating significance from each other
[control vs. Tat (10 nM): t(14) = 2.7, p = 0.018, control vs. Tat
(50 nM): t(14) = 2.7, p = 0.016, Tat (5 nM) vs. Tat (10 nM):
t(14) = 2.3, p = 0.040, Tat (5 nM) vs. Tat (50 nM): t(14) =
2.4, p = 0.031, Tat (10 nM) vs. Tat (50 nM): t(14) = 2.3, p =
0.039], except for Tat (5 nM) compared to control. As depicted
in Figure 1E, the mean (±SEM) amplitude of mIPSCs (pA)
were as follows - for control: 34.18 ± 2.46, for Tat (5 nM):
32.14 ± 2.68, for Tat (10 nM): 30.72 ± 3.37, for Tat (50 nM):
29.23 ± 3.52; n = 15. The mean amplitude of mIPSCs indicated
a significant decrease by Tat (50 nM) compared to control
[t(14) = 2.2, p = 0.049]. Heat-inactivated Tat (50 nM) revealed
no significant effects on sIPSCs (n = 9 neurons, Figure 1F) and
mIPSCs (n = 10 neurons, Figure 1G). Data were normalized
to 100% for control and indicated following percent values for
heat-inactivated Tat (50 nM): sIPSC frequency: 84.61 ± 5.97,
sIPSC amplitude: 93.71 ± 3.73, mIPSC frequency: 96.54 ±
5.17, mIPSC amplitude 92.22 ± 4.04. Overall, Tat produced
a significant decrease in action potential-dependent IPSCs
(sIPSCs) and action potential-independent IPSCs (mIPSCs),
with altering GABAergic neurotransmission presynaptically and
partially postsynaptically, depending on Tat concentration. In the
subsequent experiments Tat (10 nM) was used over Tat (50 nM)
as 10 nM is closer to mimicking the physiological condition
compared to 50 nM of Tat.
Effects of Morphine and Damgo in
Combination with Tat
It is known that acute bath application of opioids, such as
morphine, decrease GABAergic neurotransmission in different
brain regions (Bajo et al., 2014; Bobeck et al., 2014; Yousefpour
et al., 2014), however, the combined effects of opioids and Tat
on GABA release are less clear. Thus, we examined the effects of
opioids and Tat on IPSCs by performing patch-clamp recordings
on striatal MSNs with bath application of morphine (1µM) or
a highly selective µ-opioid agonist damgo (1 µM) followed by
Tat (10 nM) administration (Figure 2). The representative traces
of sIPSCs for control, morphine (1µM), and morphine + Tat
(10 nM) are shown in Figure 2A. As shown in Figure 2B (right
Panel), the mean (±SEM) frequency of sIPSCs (Hz) were as
follows - for control: 1.77 ± 0.69, for morphine (1µM): 1.37
± 0.64, for morphine + Tat (10 nM): 0.90 ± 0.29; n = 9.
Morphine significantly reducing sIPSC frequency compared to
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FIGURE 1 | Tat concentration-dependently decreased the frequency of sIPSCs and mIPSC in striatal MSNs. (A) Representative traces show sIPSCs before
and after application of Tat concentrations (5–50 nM). (B) Tat (5–50 nM) concentration-dependently decreased the mean frequency of sIPSCs (n = 13 neurons). (C)
For the mean amplitude of sIPSCs only the highest Tat concentration (50 nM) increased the mean amplitude of sIPSCs (n = 13 neurons). (D) For mIPSCs, the mean
frequency was concentration-dependently decreased by Tat (5–50 nM) (n = 15 neurons), whereas (E) the mean amplitude of mIPSCs showed no Tat effects except
for a decrease by the highest Tat (50 nM) concentration (n = 15 neurons). (F) No effects for heat-inactivated Tat (50 nM) were noted on the normalized data of the
mean frequency and mean amplitude of sIPSCs (n = 9 neurons). (G) No effects for heat-inactivated Tat (50 nM) were noted on the normalized data of the mean
frequency and mean amplitude of mIPSCs (n = 10 neurons). Data are mean ± SEM. Significance was assessed by paired Student t-tests. *p < 0.05 vs. Control,#p
< 0.05 vs. Tat (10 nM), $p < 0.05 vs. Tat (5 nM). Crt, Control; hTat, heat-inactivated Tat; MSNs, medium spiny neurons.
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FIGURE 2 | Morphine and damgo significantly decreased the frequency of IPSCs with Tat inducing a further depression of mIPSCs only in
combination with morphine. (A–C) Morphine (1µM) and Tat (10 nM) effects on IPSCs. (A) Representative traces show sIPSCs before morphine, after morphine,
and after morphine + Tat application. (B) Morphine significantly decreased the mean frequency of sIPSCs, with morphine + Tat not changing the morphine-induced
decrease in frequency of sIPSCs (n = 9 neurons). No effects were noted on the mean amplitude of sIPSCs (n = 9 neurons). (C) Morphine significantly decreased the
mean frequency of mIPSCs with a further depression by Tat administration after morphine treatment (n = 7 neurons). No effects were noted on the mean amplitude of
mIPSCs (n = 7 neurons). (D–F) Damgo (1µM) and Tat (10 nM) effects on IPSCs. (D) Representative traces show mIPSCs before damgo, after damgo, and after
damgo + Tat application. (E) Damgo significantly decreased the mean frequency of sIPSCs, with damgo + Tat not changing the damgo-induced decrease in
frequency of sIPSCs (n = 9 neurons). No effects were noted on the mean amplitude of sIPSCs (n = 9 neurons). (F) Damgo significantly decreased the mean frequency
of mIPSCs with no further depression of mIPSC frequency following Tat administration after damgo treatment (n = 11 neurons). No effects were noted on the mean
amplitude of mIPSCs (n = 11 neurons). Data are mean ± SEM. Significance was assessed by paired Student t-tests. *p < 0.05 vs. Control, #p < 0.05 vs. M. Crt,
Control; M, Morphine; D, Damgo.
control [t(8) = 3.5, p = 0.008] with no further decrease by Tat
(10 nM). As depicted in Figure 2B (left Panel), the mean (±SEM)
amplitude of sIPSCs (pA) were as follows - for control: 32.20 ±
2.90, for morphine (1µM): 33.68 ± 3.43, for morphine + Tat
(10 nM): 35.93 ± 4.07; n = 9. No effects were noted on the mean
amplitude of sIPSCs (Figure 2B). As shown in Figure 2C (right
Panel), the mean (±SEM) frequency of mIPSCs (Hz) were as
follows - for control: 0.70 ± 0.11, for morphine (1µM): 0.61 ±
0.11, for morphine+ Tat (10 nM): 0.57± 0.09; n= 7. For mIPSC
frequency a significant morphine-induced decrease of mIPSC
frequency was note compared to control [t(6) = 3.3, p = 0.016,
n= 7 neurons, Figure 2C], with being further downregulated by
Tat [morphine (1µM) vs. morphine + Tat (10 nM): t(6) = 2.7,
p = 0.034]. As depicted in Figure 2C (left Panel), the mean
Frontiers in Neuroscience | www.frontiersin.org 5 November 2016 | Volume 10 | Article 497
Xu and Fitting Tat ± Opioids Inhibit GABA Release
(±SEM) amplitude of mIPSCs (pA) were as follows - for control:
36.53 ± 3.04, for morphine (1µM): 35.09 ± 2.01, for morphine
+ Tat (10 nM): 37.14± 2.55; n= 7. No effects were noted for the
mean amplitude of mIPSCs (Figure 2C). As morphine acts on
multiple subtypes of opioid receptors, we tested the selective µ-
opioid receptor agonist damgo (1µM). Similar effects were noted
for damgo as seen with morphine. The representative traces of
mIPSCs for control, damgo (1µM), and damgo + Tat (10 nM)
are shown in Figure 2D. As shown in Figure 2E (right Panel),
the mean (±SEM) frequency of sIPSCs (Hz) were as follows - for
control: 1.14± 0.27, for damgo (1µM): 0.67± 0.19, for damgo+
Tat (10 nM): 0.66 ± 0.20; n = 9. Damgo alone and damgo + Tat
significantly decreased the mean frequency of sIPSC compared
to control [t(8) = 2.4, p = 0.045 and t(8) = 2.4, p = 0.045,
respectively]. As depicted in Figure 2E (left Panel), the mean
(±SEM) amplitude of sIPSCs (pA) were as follows - for control:
33.08 ± 4.54, for damgo (1 µM): 38.40 ± 4.45, for damgo +
Tat (10 nM): 33.69 ± 4.84, n = 9. No further downregulation of
sIPSC frequency by Tat (10 nM) administration following damgo
bath application was noted. As shown in Figure 2F (right Panel),
the mean (±SEM) frequency of mIPSCs (Hz) were as follows -
for control: 0.81 ± 0.16, for damgo (1µM): 0.37 ± 0.06, for
damgo + Tat (10 nM): 0.35 ± 0.06; n = 11. Similarly, damgo
alone and damgo + Tat reduced the mean frequency of mIPSCs
compared to control [t(10) = 2.6, p = 0.027 and t(10) = 2.7
p = 0.022, respectively]. As depicted in Figure 2F (left Panel),
the mean (±SEM) amplitude of mIPSCs (pA) were as follows -
for control: 28.77 ± 1.87, for damgo (1 µM): 30.41 ± 1.71, for
damgo + Tat (10 nM): 30.42 ± 1.77, n = 11. No effects were
noted on the mean amplitude of sIPSCs (Figure 2E) and mIPSCs
(Figure 2F). Thus, morphine and damgo decrease GABAergic
neurotransmission probably via a pre-synaptic mechanism as
the mean amplitude of IPSCs was not significantly affected by
opioids. Additionally, combined treatment of morphine and Tat
further decreased action potential-independent GABA release
presynaptically, which was not noted with combined damgo and
Tat treatment.
Combined Tat and Morphine Effects Are
Blocked by Naloxone and Partially by CTAP
To examine more in detail through which receptor the
combined Tat and morphine-induced decrease in GABAergic
neurotransmission is mediated, striatal slices were pretreated
with naloxone (1 µM), a high affinity antagonist for the
µ-opioid receptor but also some affinity for the κ-, and δ-
opioid receptors, or CTAP (1 µM), a selective µ-opioid receptor
antagonist (Figure 3). The representative traces of sIPSCs for
naloxone (1 µM) followed by Tat (10 nM) and then morphine
(1 µM) administration are shown in Figure 3A. As shown in
Figure 3B, the mean (±SEM) frequency of sIPSCs (Hz) were
as follows - for control: 0.48 ± 0.06, for naloxone (1µM): 0.49
± 0.07, for naloxone + Tat (10 nM): 0.49 ± 0.06, for naloxone
+ Tat + morphine (1µM): 0.52 ± 0.07. Pretreating striatal
slices with the opioid antagonist naloxone (1µM) revealed no
significant effects for Tat (10 nM) or combined Tat and morphine
(1µM) treatment on the mean frequency of sIPSCs (n = 12
neurons, Figure 3B) and the mean frequency of mIPSCs (n
= 10 neurons, Figure 3C). As shown in Figure 3C, the mean
(±SEM) frequency of mIPSCs (Hz) were as follows - for control:
0.45 ± 0.09, for naloxone (1µM): 0.44 ± 0.08, for naloxone
+ Tat (10 nM): 0.44 ± 0.10, for naloxone + Tat + morphine
(1µM): 0.45 ± 0.09. No significant effects were noted on the
mean amplitude of sIPSCs and mIPSCs (data not shown). To
test if the combined Tat (10 nM) and morphine (1µM) effects
were µ-opioid receptor specific, CTAP (1 µM) was used as
a pretreatment (Figures 3D–F). The representative traces of
mIPSCs for CTAP (1 µM) followed by Tat (10 nM) and then
morphine (1µM) administration are shown in Figure 3D. As
shown in Figure 3E, the mean (±SEM) frequency of sIPSCs
(Hz) were as follows - for control: 0.70 ± 0.17, for CTAP
(1µM): 0.66 ± 0.18, for CTAP + Tat (10 nM): 0.63 ± 0.14,
for CTAP + Tat + morphine (1µM): 0.65 ± 0.20. Similar to
naloxone, CTAP (1 µM) revealed no significant effects for Tat
(10 nM) or combined Tat and morphine (1µM) treatment on
the mean frequency of sIPSCs (n = 11 neurons, Figure 3E). As
shown in Figure 3F, the mean (±SEM) frequency of mIPSCs
(Hz) were as follows - for control: 0.51 ± 0.07, for CTAP
(1µM): 0.50 ± 0.07, for CTAP + Tat (10 nM): 0.48 ± 0.07, for
CTAP + Tat + morphine (1µM): 0.44 ± 0.06. Interestingly,
whereas CTAP (1 µM) blocked the significant effects of Tat (10
nM) on the mean frequency of sIPSCs, the significant effect
of combined Tat and morphine (1µM) treatment on mIPSC
frequency was not blocked [CTAP (1µM) + Tat (10 nM) vs.
CTAP + Tat + morphine (1µM) t(9) = 3.0, p = 0.016, n =
10 neurons, Figure 3F]. No significant effects were noted on the
mean amplitude of sIPSCs and mIPSCs (data not shown). Thus,
the significant decrease of GABA release with combined Tat and
morphine treatment appears to involve predominantly µ-opioid
receptor-related mechanisms.
Tat Effects on IPSCs Depend on
Extracellular and Intracellular Calcium
To understand the mechanisms by which Tat decreases
GABAergic synaptic neurotransmission, we examined the
involvement of extracellular calcium, voltage-gated calcium
channels, and intracellular calcium (Figure 4). Manipulating
extracellular and intracellular calcium decreased the frequency
of sIPSCs by 33.3% when removing extracellular calcium from
the aCSF [control vs. 0 Ca2+ control: t(12) = 4.1, p < 0.001,
n = 13 neurons], by 43.9% when blocking the voltage-gated
calcium channels with CdCl2 [200 µM; control vs. CdCl2
control: t(9) = 3.5, p = 0.006, n = 10 neurons], and by 26.9%
when depleting intracellular calcium stores with the endoplasmic
reticulum calcium pump inhibitor thapsigargin [control vs.
thapsigargin control: t(9) = 2.3, p = 0.050, n = 10 neurons;
Figure 4A]. Importantly, whereas Tat (10 nM; 0.91 ± 0.22)
significantly reduced the frequency of sIPSCs in the presence
of normal aCSF (1.34 ± 0.39) [t(12) = 2.5, p = 0.027, n = 13
neurons], no Tat effects were noted when extracellular calcium
was removed from the aCSF [n = 13 neurons; control: 0.61 ±
0.09, Tat (10 nM): 0.56 ± 0.07], voltage-gated calcium channels
were blocked with CdCl2 [200µM; n = 10 neurons; control:
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FIGURE 3 | Naloxone and partially CTAP blocked the effects of Tat and/or morphine on the frequency of IPSCs. (A–C) Naloxone (1 µM), Tat (10 nM), and
morphine (1 µM) effects on the mean frequency of IPSCs. (A) Representative traces show sIPSCs before and after naloxone treatment, followed by Tat, and morphine
application. (B) No significant effects were noted on the mean frequency of sIPSCs for Tat or combined Tat and morphine treatment in the presence of naloxone (n =
12 neurons). (C) Similarly, in the presence of naloxone, no significant effects were noted on the mean frequency of mIPSCs for Tat (10 nM) or combined Tat and
morphine treatment (n = 10 neurons). (D–F) CTAP (1µM), Tat (10 nM) and morphine (1 µM) effects on the mean frequency of IPSCs. (D) Representative traces show
mIPSCs before and after CTAP treatment, followed by Tat, and morphine (1µM) application. (E) No significant effects were noted on the mean frequency of sIPSCs
for Tat or combined Tat and morphine treatment in the presence of CTAP (n = 11 neurons). (F) In the presence of CTAP, combined Tat and morphine treatment
significantly downregulated the mean frequency of mIPSCs compared to Tat alone (n = 10 neurons). Data are mean ± SEM. Significance was assessed by paired
Student t-tests. #p < 0.05 vs. CTAP + Tat. Crt, Control; M, Morphine.
0.67 ± 0.17, Tat (10 nM): 0.61 ± 0.16], or intracellular calcium
stores were depleted from calcium with thapsigargin [1 µM;
n = 9 neurons; control: 0.42 ± 0.10, Tat (10 nM): 0.46 ± 0.10;
Figure 4A], indicating that extracellular and intracellular calcium
are necessary for the Tat-induced decrease in sIPSC frequency.
No significant overall treatment effects were noted for the
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FIGURE 4 | Extracellular and intracellular calcium contribute to the significant Tat (10 nM) effects on the mean frequency of IPSCs. (A) The significant Tat
(10 nM) effect on the mean frequency of sIPSCs (n = 13 neurons) was blocked by zero extracellular Ca2+ (n = 13 neurons), CdCl2 (200 µM, n = 10 neurons), and
thapsigargin (1 µM, n = 10 neurons). (B) No Tat effects were noted on the mean amplitude of sIPSCs. (C) Representative traces show sIPSCs before and after
application of Tat (10 nM) in the presence of normal aCSF, zero extracellular Ca2+, CdCl2 (200 µM), and thapsigargin (1 µM). (D) The significant Tat (10 nM) effect on
the mean frequency of mIPSCs (n = 15 neurons) was blocked by zero extracellular Ca2+ (n = 8 neurons), CdCl2 (200 µM, n = 9 neurons), and thapsigargin (1 µM,
n = 10 neurons). (E) No Tat effects were noted on the mean amplitude of mIPSCs in any condition. Data are mean ± SEM. Significance was assessed by paired
Student t-tests. *p < 0.05 vs. Control of corresponding condition. aCSF, artificial cerebrospinal fluid; Crt, Control; Thap, Thapsigargin.
amplitude of sIPSCs for any condition (Figure 4B). As shown
in Figure 4B, the mean (±SEM) amplitude of sIPSCs (pA)
for the different conditions were as follows—control condition:
normal aCSF: 37.40 ± 4.09, Tat (10 nM): 43.82 ± 4.00; zero
extracellular Ca2+: aCSF: 30.24 ± 1.55, Tat (10 nM): 29.99 ±
1.85; CdCl2: aCSF: 27.69 ± 1.97, Tat (10 nM): 24.16 ± 2.10;
thapsigargin: aCSF: 30.24 ± 2.05, Tat (10 nM): 28.35 ± 1.55.
For mIPSCs, the representative traces before and after Tat
application for each condition are shown in Figure 4C. Similar
to effects on sIPSCs, Tat (10 nM; 0.92 ± 0.32) significantly
downregulated the frequency of mIPSCs in normal aCSF (1.10
± 0.36) [t(14) = 2.7, p = 0.018, n = 15 neurons], but no
significant Tat effects were noted in the absence of extracellular
calcium [n = 8 neurons; control: 0.55 ± 0.09, Tat (10 nM): 0.49
± 0.07], in the presence of CdCl2 [200 µM; n = 9 neurons;
control: 0.50 ± 0.31, Tat (10 nM): 0.54 ± 0.31], and in the
presence of thapsigargin [1µM; n = 10 neurons; control: 0.32
± 0.06, Tat (10 nM): 0.30 ± 0.06; Figure 4D]. Further, no
significant Tat (10 nM) effects were noted for the amplitude of
mIPSCs (Figure 4E). As shown in Figure 4E, the mean (±SEM)
amplitude of mIPSCs (pA) for the different conditions were
as follows—control condition: normal aCSF: 34.18 ± 2.46, Tat
(10 nM): 30.72 ± 3.37; zero extracellular Ca2+: aCSF: 28.36 ±
1.46, Tat (10 nM): 27.69 ± 1.39; CdCl2: aCSF: 22.83 ± 1.37, Tat
(10 nM): 21.66 ± 1.39; thapsigargin: aCSF: 25.90 ± 1.76, Tat (10
nM): 24.47± 2.32. Thus, the significant Tat (10 nM) effects on the
frequency of IPSCs were abolished when removing extracellular
and/or intracellular calcium, indicating that extracellular and
intracellular calcium are necessary for the Tat-induced decrease
in GABA release.
DISCUSSION
In the present study, we investigated (1) the HIV-1 Tat effects
on the GABAergic neurotransmitter system, (2) the combined
effects of Tat and opioids on the GABAergic system, and (3)
the underlying mechanisms by which Tat affects GABAergic
neurotransmission.
Tat Concentration-Dependently Decreases
GABAergic Neurotransmission
It is well known that Tat is excitotoxic by activating
glutamatergic NMDA receptors (Magnuson et al., 1995;
Haughey et al., 2001; Pérez et al., 2001; Longordo et al., 2006;
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Li et al., 2008; Aksenov et al., 2012). Further, Tat has been
shown to directly affect glutamatergic neurotransmission by
increasing the frequency of miniature excitatory postsynaptic
currents (mEPSCs) (Brailoiu et al., 2008) and neuronal
excitability (Ngwainmbi et al., 2014; Fitting et al., 2015).
However, as glutamate and GABA are the most abundant
neurotransmitters in the brain, neuronal excitability is
critically dependent on the level of inhibition, and accordingly
changes of inhibitory synaptic efficacy has great impact on
neuronal function and neuronal network processing (Petroff,
2002).
The present study provides direct evidence that Tat
concentration-dependently decreases inhibitory transmitter
release in the dorsolateral striatum. The observation that
Tat alters sIPSCs and mIPSCs in medium spiny GABAergic
projection neurons (MSNs) indicates that Tat has effects on
intrinsic interneuron excitability and modifies the GABA release
machinery. Specifically, our data suggest that action potential
(AP)-independent IPSCs (mIPSCs) contribute mostly to overall
IPSCs in our MSN recordings. It is known that AP-independent
spontaneous vesicular release of GABA in the CNS mediates
mIPSCs (Axmacher et al., 2004). Another source of mIPSCs is
known to be the reversal of GABA transporter (GAT), which may
result in additional GABA release under certain physiological
conditions (Allen et al., 2004; Wu et al., 2007; Jin et al., 2011).
Further, as in the present study glutamate receptor blockers were
present in the bath, the GABA component of the AP-dependent
synaptic potential, which arises largely from collateral branches
of the MSNs themselves, was inhibited, thus contributing to
smaller AP-dependent GABA release (sIPSCs). The marked
reduction of the mean frequency of IPSCs by Tat (10 nM),
without any change in the mean amplitude of IPSCs, suggests
that Tat acts at presynaptic GABAergic terminals and suppresses
inhibitory synaptic input to MSNs. As a decrease in inhibitory
synaptic inputs would facilitate an increase in postsynaptic
activity, the presynaptic inhibition of IPSCs may play a role in
the excitatory effects of Tat on the activities of MSNs, besides
direct excitation through postsynaptic actions (Kim et al., 2008).
Interestingly, in the present study, the highest concentration
of Tat (50 nM) altered the amplitude of IPSCs, suggesting that
Tat may modulate IPSCs also through postsynaptic mechanisms,
such as alterations in number of postsynaptic receptors,
postsynaptic sensitivity or conductance. The discrepancy of Tat
(50 nM) increasing the amplitude of sIPSCs but decreasing
the amplitude of mIPSCs is not well understood. For the
increased Tat effects noted on the sIPSC amplitude, AP-driven
events may play a role due to intrinsic properties of the
presynaptic cell or network activity. It is suggested that tonically
active GABAergic interneurons might contribute to the Tat-
induced increase in sIPSC amplitude as fast-spiking parvalbumin
interneurons in the pyramidal layer have been demonstrated to
be selectively vulnerable to Tat (Marks et al., 2016). Additionally,
other types of GABAergic interneurons make connections
with the spiny neurons, including interneurons that express
tyrosine hydroxylase (Xenias et al., 2015) and neuropeptide Y
(Beatty et al., 2012). As we did notice a decrease in sIPSC
frequency, it should be noted that the probability of opening also
depends upon how much GABA is released (presynaptic), which
influences the sIPSC frequency. In contrast, mIPSC amplitude
is AP-independent, thus Tat effects on postsynaptic receptors,
such as single channel conductance through an open GABA
pore, or a change in the number of channels could contribute
to a postsynaptic decrease in mIPSC amplitude. Further, the
decrease in mIPSC amplitude could be due to the internalization
of specific receptors. TNF-α is known to causes internalization of
GABAA receptors, resulting in fewer surface GABAA receptors
and a decrease in inhibitory synaptic strength (Stellwagen et al.,
2005). TNF-α has been shown to play a central role in initiating
inflammatory cascades in Tat-exposed astroglia and microglia
(Benveniste and Benos, 1995; Luo et al., 2003; El-Hage et al.,
2008) as well as in HIV-infected patients (Zhao et al., 2014). It
is important to note however, that the effect on amplitude was
only noticed for the high Tat (50 nM) concentration, in contrast
to Tat (10 nM) that did not produce significant effects on ISPC
amplitude.
Further, the effects of Tat on the inhibitory GABAergic system
indicate to be variable with multiple studies reporting different
results (Brailoiu et al., 2008; Fitting et al., 2013; Hargus and
Thayer, 2013; Zucchini et al., 2013; Marks et al., 2016). A recent
study demonstrated that Tat applied in vitro as well as expressed
in the brain in vivo induced a decrease in GABA exocytosis
in the cortex, while GABA exocytosis was unchanged in the
hippocampus (Zucchini et al., 2013). Further, it appears that Tat
has various effects on different inhibitory synaptic proteins, with
dowregulating synaptotagmin 2 (Syt2) in the hippocampus of
Tat transgenic mice (Fitting et al., 2013), whereas upregulating
gephyrin in the hippocampus in vitro and in vivo (Fitting et al.,
2013; Hargus and Thayer, 2013). Thus, depending on the brain
region and the inhibitory synaptic input the GABAergic system
might be differently affected by Tat.
Overall the present study demonstrates that Tat modulates
inhibitory GABAergic influence on MSNs in the dorsolateral
striatum through both presynaptic and postsynaptic
mechanisms, depending on Tat concentration.
Differential Effects of Tat in Combination
with Morphine or Damgo on the
GABAergic System
Multiple studies have investigated the effects of opioids on
GABAergic synaptic transmission with demonstrating that
opioids inhibit GABA-mediated neurotransmission (Vaughan
and Christie, 1997; Vaughan et al., 1997; Zhang et al., 2015).
As reported in the present study it has been shown previously
that opioids decrease the frequency of IPSCs but do not change
the amplitude of IPSCs, indicating that neurotransmission is
inhibited presynaptically (Vaughan and Christie, 1997; Vaughan
et al., 1997). More interestingly, whereas a combined effect
was noted for morphine and Tat on the frequency of mIPSCs,
the selective µ-opioid receptor agonist damgo did not further
downregulate mIPSC frequency in the presence of Tat. It is
known that morphine and damgo, which primarily act on the
µ-opioid receptors, have high efficacy in inhibiting calcium
channels, whereas damgo but not morphine has high efficacy
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FIGURE 5 | Summary of the effects on inhibitory GABAergic neurotransmission by HIV-1 Tat and opioids. Spontaneous inhibitory postsynaptic currents
(sIPSCs) and miniature IPSCs (mIPSCs) were recorded from medium spiny neurons (MSNs) located in the dorsolateral striatum. A significant decrease in sIPSC
frequency and mIPSC frequency was noted for Tat (10 nM) treatment. The significant Tat (10 nM) effect on the frequency of IPSCs was abolished when removing
extracellular calcium (0 Ca2+), blocking voltage-dependent Ca2+ channels with cadmium chloride (CdCl2), and depleting intracellular endoplasmic reticulum calcium
stores with thapsigargin, indicating that extracellular and intracellular calcium are necessary for the Tat-induced decrease in GABA release. For opioids, including
morphine and damgo, separately and in combination with Tat, a significant decrease was noted for sIPSC frequency and mIPSC frequency, that was only potentiated
for mIPSCs when combining Tat with morphine, but not damgo. Additionally, pretreatment with naloxone or CTAP prevented the combined Tat and morphine-induced
decrease in sIPSCs frequency, whereas only naloxone, but not CTAP, prevented the combined Tat and morphine effect on mIPSCs frequency. It is hypothesized that
the decrease of GABA release by Tat and opioids is primarily mediated via µ-opioid receptors with additive effects on GABA release being potentially mediated via
additional opioid receptors. AP, action potential; MSN, medium spiny neuron; Ca2+, calcium; [Ca2+]i, intracellular calcium; sIPSC, spontaneous inhibitory
postsynaptic currents; mIPSC, miniature inhibitory postsynaptic currents.
for p38mitogen-activated protein kinase activation that regulates
inflammation and is activated by cytokine production (Tibbles
and Woodgett, 1999; Tan et al., 2009). As Tat has been shown
to activate p38 mitogen-activated protein kinase (Li et al., 2005;
Li and Lau, 2007; Gupta et al., 2010), differential caspase-
dependent pathways could be used by Tat and morphine to
inhibit GABA release and cause a downregulation when applied
in combination.
Additionally, in contrast to damgo, morphine is not selective
to µ-opioid receptors but also has effects on other opioid
receptors. That other subtypes of opioid receptors besides
the µ-opioid receptor seem to be involved in the combined
opioid and Tat effects on GABAergic neurotransmission
is supported by the finding that naloxone but not CTAP
was able to block the combined opioid and Tat effects
on GABAergic neurotransmission, specifically for mIPSC
frequency. It should be noted that the µ-opioid receptor
inhibition with CTAP blocked combined Tat and morphine-
induced decrease in sIPSC frequency, but not in mIPSC
frequency. The involvement of δ-opioid receptors has been
shown in a previous study, indicating that a selective δ-opioid
receptor agonist (D-Pen(2,5)-enkephalin, DPDPE) but not a
selective κ-opioid receptors agonist [(+)-(5 alpha,7 alpha,8
beta)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-
8-yl]-benzeneacetamide; U-69593] decreased IPSCs with a
co-localization of δ-opioid receptors and dopamine 1 (D1)-type
receptors in the rat dorsolateral striatum (Ambrose et al., 2006).
Naloxone is a high affinity antagonist for the µ-opioid receptor
but also has some affinity on the κ-, and δ-opioid receptors,
whereas CTAP is a selective µ-opioid receptor antagonist.
Previous studies have shown that κ-, and δ-opioid receptors
are involved in the regulation of inhibitory transmission (Ford
et al., 2006; Bosse et al., 2014; Gilpin et al., 2014). Specifically,
δ-opioid receptors inhibit GABA release via a presynaptic
Frontiers in Neuroscience | www.frontiersin.org 10 November 2016 | Volume 10 | Article 497
Xu and Fitting Tat ± Opioids Inhibit GABA Release
site of action in the striatum (Jiang and North, 1992) and are
localized mainly to presynaptic terminals of inhibitory synapses
(Svingos et al., 1998). In addition to a regulating function,
δ-opioid receptors have also been shown to downregulate
GABAA receptor expression in the cortex of δ-opioid receptor
transgenic mice (Feng et al., 2011). Besides morphine’s effects
on µ- opioid receptors but also on κ-, and δ-opioid receptors,
it additionally has been shown that morphine can activate
nociceptin/orphanin FQ peptide receptors (Ueda et al., 2000;
Kest et al., 2001). The specific receptor that might contribute to
the further downregulation of GABA release by combined Tat
and morphine treatment can not be conclusively determined in
the present study and needs further investigation.
Additionally, it needs to be pointed out that certain
subpopulation of MSNs might show differential responsiveness
to treatments, such as Tat and opioids. µ-opioid receptors are
generally thought to reside in striosome (not matrix) MSNs (Cui
et al., 2014). Even though µ-opioid receptors are expressed in
both the D1-type MSNs of the direct pathway and D2-type MSNs
of the indirect pathway, it appears that at least in some striosomes
there is an overabundance of D1-type MSNs (Fujiyama et al.,
2011; Watabe-Uchida et al., 2012; Cui et al., 2014), and further
µ-opioid receptors might be specifically located in D1-MSNs of
the direct pathway (Gerfen, 1985; Crittenden and Graybiel, 2011;
Cui et al., 2014). Thus, the differential contribution of the D1-type
MSNs and D2-type MSNs to the effects of morphine and damgo
in the context of Tat exposure needs to be assessed in more detail.
Decrease of GABAergic
Neurotransmission by Tat Is Dependent on
Extracellular and Intracellular Calcium
Studies have demonstrated that Tat alters calcium with
inducing abnormal and excessive calcium influx and increasing
intracellular calcium release that consequentially elevates
cytosolic free calcium levels and leads to neurotoxicity (Haughey
and Mattson, 2002; Hu, 2016). However, little research has been
done to examine the involvement of calcium in the context of
Tat on GABAergic synaptic neurotransmission. GABA has been
shown to be released via calcium-dependent mechanisms that
involve different subtypes of voltage-gated calcium channels
(Alamilla and Gillespie, 2013; Nelson et al., 2014). The present
study demonstrates that the observed Tat-induced decrease in
GABAergic neurotransmission is dependent on extracellular and
intracellular calcium. It is known that Tat increases calcium via
inositol 1,4,5-trisphosphate (IP3)-regulated and/or ryanodine-
regulated pools (Lipton, 1994; Nath and Geiger, 1998; Haughey
et al., 1999; Fitting et al., 2014) with subsequent increases
in calcium that enters the cell extracellularly via voltage-
gated calcium channels (Bonavia et al., 2001). An increase in
intracellular calcium could thus, account for the reduction in
the amplitude of mIPSCs seen in the present study, as increases
in intracellular calcium can lead to a suppression of the mean
amplitude of IPSCs (Brussaard et al., 1996). Interestingly, there
was an increase noted for the mean amplitude of sIPSCs by Tat
(50 nM), indicating that the AP-dependent release of GABA from
transmitter vesicles was decreased for frequency but increased
for amplitude. As the increase in amplitude was only seen for
sIPSCs and not mIPSCs the amplitude change could be related to
a selective effect on intrinsic interneuron excitability and needs
to be further studied.
The present study further suggests that the effects of Tat on
GABA release appear to be mediated via µ-opioid receptors,
as CTAP was able to block the Tat-induced decrease of GABA
release. Opioid receptors are widely expressed in the striatum and
the GABA modulation by µ-opioid receptors is consistent with
anatomical data showing that neurons are immunopositive for
µ-opioid receptors on pre- (axonal) and postsynaptic (dendritic)
locations in different brain regions (Arvidsson et al., 1995;
Drake and Milner, 1999). Additionally, it is known that µ-
opioid receptors are extensively co-localized with paravalbumin-
positive neurons (Drake and Milner, 2006), with a recent
study demonstrating that neurons expressing parvalbumin in
the pyramidal layer and neurons expressing somatostatin in
stratum oriens are selectively vulnerable to Tat (Marks et al.,
2016). Overall, the present study demonstrates that the Tat-
induced decrease in GABAergic neurotransmission is dependent
on extracellular and intracellular calcium, potentially involving a
µ-opioid receptor-related pathway.
CONCLUSIONS
A summary of the findings of the present study is outlined
in Figure 5. Our findings indicate that Tat as well as opioids,
including morphine and damgo, separately, decreased AP-
dependent and AP-independent GABA release in the striatum
via aµ-opioid receptor-related mechanism, with Tat effects being
dependent on extracellular and intracellular calcium. Combined
Tat and opioid treatment revealed additive effects on GABA
release only for Tat combined with morphine but not with
damgo, which was blocked by naloxone but not CTAP. Based
on the findings of the present study the decrease of GABA
release by Tat and opioids is primarily mediated via µ-opioid
receptors with additive effects on GABA release being potentially
mediated via additional opioid receptors. Importantly, further
studies are necessary to examine the effects of chronic Tat
and opioid exposure on GABAergic neurotransmission to
guide future research on HAND in the context of opiate
drug use.
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